Business Context and Reporting Period
This Form 8-K Current Report was filed by Supernus Pharmaceuticals, Inc. on November 1, 2023, regarding an event that occurred on November 2, 2023. The filing addresses a regulatory milestone for the Company's pipeline rather than a standard financial reporting period.
Key Financial Metrics
This filing does not contain financial statements, revenue figures, profit data, cash flow metrics, debt levels, or liquidity ratios. The document is a current report focused on a specific corporate event.
Material Changes
The primary material change reported is the regulatory status of the Company's new drug application (NDA):
- Product: Apomorphine infusion device (SPN-830).
- Indication: Continuous treatment of motor fluctuations (OFF episodes) in Parkinson's disease (PD).
- Event: The U.S. Food and Drug Administration (FDA) acknowledged the resubmission of the NDA.
- Status: The resubmission is now considered filed.
- Timeline: A Prescription Drug User Fee Act (PDUFA) goal date has been set for April 5, 2024.
Guidance, Outlook, and Risks
The filing includes standard forward-looking statements regarding the Company's plans and strategies. Management notes that these statements are subject to risks and uncertainties, including those detailed in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2022. The Company explicitly states it undertakes no obligation to update these forward-looking statements.
Investor Verification Checklist
- Verify the PDUFA date of April 5, 2024, for the SPN-830 NDA.
- Review the full text of the press release dated November 2, 2023 (Exhibit 99.1) for additional context.
- Consult the most recent Form 10-K for detailed risk factors associated with the drug development process.
- Monitor future filings for the FDA's final decision on the NDA prior to the PDUFA date.